Debate: Treatment of patients with recurrent ovarian cancer should be treated with antiangiogenic agents in combination with chemotherapy Journal Article

  

Authors:	Boruta, D.; Farley, J.; Birrer, M. J.; Sabbatini, P.
Article Title:	Debate: Treatment of patients with recurrent ovarian cancer should be treated with antiangiogenic agents in combination with chemotherapy
Keywords:	cancer survival; unclassified drug; clinical trial; review; sorafenib; angiogenesis inhibitor; bevacizumab; doxorubicin; erlotinib; fluorouracil; placebo; sunitinib; cancer combination chemotherapy; drug efficacy; drug safety; hypertension; unspecified side effect; gemcitabine; paclitaxel; cancer patient; topotecan; recurrent cancer; antineoplastic agent; colorectal cancer; imatinib; carboplatin; unindexed drug; progression free survival; ovary cancer; breast cancer; lung non small cell cancer; cyclophosphamide; antineoplastic activity; irinotecan; panitumumab; heart infarction; thromboembolism; folinic acid; gefitinib; 2,4 dimethyl 5 (2 oxo 1h indol 3 ylmethylene) 3 pyrrolepropionic acid; 5,6 dimethylxanthenone 4 acetic acid; aflibercept; cediranib; combretastatin a4; imc 1121 b; pazopanib; vandetanib; vatalanib; xl 999; ovary carcinoma; transient ischemic attack; unstable angina pectoris; vascular tumor
Journal Title:	Clinical Ovarian Cancer
Volume:	2
Issue:	1
ISSN:	1941-4390
Publisher:	Elsevier Inc.
Date Published:	2009-01-01
Start Page:	12
End Page:	18
Language:	English
DOI:	10.3816/COC.2009.n.002
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-77953465993&partnerID=40&md5=aef742acd1d4a74557f9eca2e46f003c
Notes:	--- - "Export Date: 30 November 2010" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/159